Form 4: aTYR Pharma CEO Granted 1.5M Stock Options

aTYR Pharma's President and CEO, Sanjay Shukla, was granted 1.5 million employee stock options with an exercise price of $0.7127, vesting over three years.

Summary

• Sanjay Shukla, President and CEO of aTYR PHARMA INC, was granted 1,500,000 employee stock options.
• The options have an exercise price of $0.7127 per share.
• Vesting for these options will occur in 36 equal monthly installments, commencing on February 9, 2026.
• The options will be fully exercisable on January 9, 2029.
• The expiration date for these options is January 9, 2036.
• Accelerated vesting is stipulated upon termination without cause following a change of control of the issuer.

Sentiment

Score: 6

Explanation: The grant of stock options to the CEO is a standard practice to align executive incentives with shareholder value. It reflects a commitment to the company's long-term performance, which is generally viewed as a slightly positive or neutral event.

Positives

• The grant of 1,500,000 employee stock options to the President and CEO aligns management's long-term interests with shareholder value creation.
• The three-year vesting schedule encourages sustained performance and commitment from leadership.

Negatives

• No direct negatives are presented in this Form 4 filing, which is a disclosure of an equity grant.

Risks

• Potential future dilution for existing shareholders if the options are exercised, increasing the number of outstanding shares.
• The value of the options is tied to the company's stock performance, meaning the CEO's compensation from these options is at risk if the stock price does not appreciate above the exercise price.

Future Outlook

The vesting schedule for the employee stock options extends through January 9, 2029, indicating a long-term incentive structure for the President and CEO. The options expire on January 9, 2036, providing a significant window for potential exercise.

Industry Context

Granting stock options to executive leadership is a common practice in the biotechnology and pharmaceutical industries, particularly for companies like aTYR Pharma, to incentivize long-term performance, retain key talent, and align management's financial interests with those of shareholders. This practice is standard across many growth-oriented sectors.

Comparison to Industry Standards

• The grant of stock options to a CEO is a standard component of executive compensation packages across the biotech and broader public company landscape.
• While the specific number of options (1.5 million) and exercise price ($0.7127) are company-specific, the mechanism of using performance-based equity awards with multi-year vesting schedules is consistent with industry best practices for executive incentive alignment.
• Similar grants are observed at comparable small-to-mid cap biotech firms, though the scale varies based on company size, stage of development, and market capitalization.

Related Party Transactions

• The grant of employee stock options to the President and CEO is a form of compensation and a standard, disclosed compensation event with a related party (an executive).

Stakeholder Impact

• Shareholders: Potential for increased alignment between the CEO's interests and shareholder value. Potential for future dilution if options are exercised.
• Employees: May signal confidence in the company's future, potentially boosting morale.
• Management: Provides a significant long-term incentive tied to company performance.

Next Steps

• Continued vesting of the 1,500,000 employee stock options over the next 36 months, starting February 9, 2026.
• Potential exercise of options by the CEO once they become vested and if the stock price is favorable.

Key Dates

Keywords

ATYR, aTYR Pharma, stock options, insider transaction, CEO, equity compensation, executive compensation, vesting